Clinical Trial

Anti-PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases

Study acronym: ABC
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this research project is to test the effectiveness of nivolumab versus nivolumab together with ipilimumab for the treatment of melanoma brain metastases. Patients are eligible to join this study if they are aged 18 years or above and have been diagnosed with melanoma with brain metastases.
Protocol Amendment History 17 amendments
This ClinicalTrials.gov record has been amended 17 times since 2015-02-26; most recent amendment 2025-12-03.
Status change: Recruiting → Active, Not Recruiting 2017-05-02
Trial Details
NCT Number NCT02374242
Lead Sponsor Melanoma Institute Australia
Collaborators: Melanoma and Skin Cancer Trials Limited, Bristol-Myers Squibb
Conditions Melanoma, Brain Metastases
Enrollment 76 participants
Start Date 2014-11-04
Primary Completion 2017-09-04 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2025-12-10